A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer

被引：7

作者：

Puglisi, Fabio ^{[1
]}

Bisagni, Giancarlo ^{[2
]}

Ciccarese, Mariangela ^{[3
]}

Fontanella, Caterina ^{[1
]}

Gamucci, Teresa ^{[4
]}

Leo, Luigi ^{[5
]}

Molino, Annamaria ^{[6
]}

Silva, Rosa Rita ^{[7
]}

Marchetti, Paolo ^{[8
,9
]}

机构：

[1] Univ Udine, Dept Med & Biol Sci, Udine, Italy

[2] Azienda Osped ASMN, Dept Oncol, Oncol Unit, Ist Ricovero & Cura Carattere Sci, Reggio Emilia, Italy

[3] Vito Fazzi Hosp, Dept Med Oncol, Lecce, Italy

[4] ASL Frosinone, Med Oncol Unit, Frosinone, Italy

[5] Azienda Osped Colli, Oncol Unit, Naples, Italy

[6] Univ Verona, Verona, Italy

[7] ASUR Marche AV2 Fabriano, Med Oncol Unit, Fabriano, Italy

[8] Sapienza Univ Rome, Med Oncol, St Andrea Hosp, Rome, Italy

[9] IDI IRCCS, Rome, Italy

来源：

FUTURE ONCOLOGY | 2016年 / 12卷 / 22期

关键词：

angiogenesis; bevacizumab; breast cancer; PROGRESSION-FREE SURVIVAL; PHASE-III TRIAL; CONTAINING THERAPY; OPEN-LABEL; NEOADJUVANT CHEMOTHERAPY; PLUS BEVACIZUMAB; TARGETED THERAPIES; AND/OR BEVACIZUMAB; LOCALLY RECURRENT; CLINICAL-PRACTICE;

D O I：

10.2217/fon-2016-0295

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

To gain consensus on the role of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer, a panel of expert oncologists experienced in treating patients with metastatic breast cancer in Italy participated in a Delphi consensus study. The panel reached a full consensus on the efficacy of bevacizumab plus paclitaxel and the clinical meaningfulness of the progression-free survival benefit compared with paclitaxel alone, despite the lack of an overall survival effect in clinical trials. The participants agreed that real-world data support the effectiveness and well-defined safety profile of the regimen. Views on the use of bevacizumab plus paclitaxel in specific patient populations were not unanimous and clinical judgment remains important. Nevertheless, a high level of agreement was reached.

引用

页码：2589 / 2602

页数：14

共 50 条

[21] A phase I/II study of docetaxel/epirubicin/bevacizumab (DEB) as first-line therapy for metastatic, HER2-negative breast cancer (MBC).
Mavroudis, D.
Boukovinas, I.
Christophyllakis, C.
Xenidis, N.
Papakotoulas, P.
Malamos, N. A.
Kakolyris, S.
Polyzos, A.
Georgoulias, V.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[22] Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
J. Salvador
L. Manso
J. de la Haba
A. Jaen
E. Ciruelos
M. C. de Villena
M. Gil
A. Murias
A. Galan
C. Jara
J. Bayo
J. M. Baena
J. Casal
J. R. Mel
I. Blancas
P. Sanchez Rvira
Clinical and Translational Oncology, 2015, 17 : 160 - 166
[23] First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients
Miles, D. W.
Dieras, V.
Cortes, J.
Duenne, A. -A.
Yi, J.
O'Shaughnessy, J.
ANNALS OF ONCOLOGY, 2013, 24 (11) : 2773 - 2780
[24] Primary endpoints in first-line trials in patients with HER2-negative/-unknown metastatic breast cancer (MBC)
Kuemmel, S.
Mueller, V
Lux, M. P.
Weyer, G.
Pintoffl, J. P.
Jackisch, C.
ONKOLOGIE, 2012, 35 : 66 - +
[25] Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study
Manso, Luis
Garcia Palomo, Andres
Perez Carrion, Ramon
Cassinello, Javier
Gallegos Sancho, Isabel
Chacon Lopez-Muniz, Ignacio
Olier, Clara
Fernandez-Aramburo, Antonio
Llorca, Cristina
Gonzalez, Xavier
Llorente, Rosa
Torregrosa, Dolores
Alvarez, Inaki
Galve, Elena
Bueno, Coralia
Garau, Isabel
Garcia, Maria Jose
Gonzalez-Santiago, Santiago
Ballesteros, Ana Isabel
Blanco, Esperanza
Galan, Antonio
Gonzalez, Sonia
Perello, Antonia
Cortes-Funes, Hernan
Gravalos, Cristina
ANTICANCER RESEARCH, 2015, 35 (12) : 6941 - 6950
[26] The efficacy of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer: a meta-analysis of randomized controlled trials
Wang, Xuan
Huang, Chun
Li, Man
Gu, Yanjun
Cui, Yanfen
Li, Yan
TUMOR BIOLOGY, 2014, 35 (05) : 4841 - 4848
[27] First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study
Hardy-Bessard, Anne-Claire
Brocard, Fabien
Clatot, Florian
Lortholary, Alain
You, Benoit
Grenier, Julien
Martin-Babau, Jerome
Lucas, Brigitte
Meunier, Jerome
Ferrero, Jean-Marc
Savoye, Aude-Marie
Marti, Adina
Despax, Raymond
Moullet, Isabelle
Emile, George
BREAST, 2020, 54 : 256 - 263
[28] A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer
Gamucci, Teresa
Mentuccia, Lucia
Natoli, Clara
Sperduti, Isabella
Cassano, Alessandra
Michelotti, Andrea
Di Lauro, Luigi
Sergi, Domenico
Fabi, Alessandra
Sarobba, Maria G.
Marchetti, Paolo
Barba, Maddalena
Magnolfi, Emanuela
Maugeri-Sacca, Marcello
Rossi, Ernesto
Sini, Valentina
Grassadonia, Antonino
Pellegrini, Domenica
Astone, Antonino
Nistico, Cecilia
Angelini, Franco
Vaccaro, Angela
Pellegrino, Arianna
De Angelis, Claudia
Palleschi, Michela
Moscetti, Luca
Bertolini, Ilaria
Buglioni, Simonetta
Giordano, Antonio
Pizzuti, Laura
Vici, Patrizia
JOURNAL OF CELLULAR PHYSIOLOGY, 2017, 232 (06) : 1571 - 1578
[29] Phase II study of nab-paclitaxel, bevacizumab, and gemcitabine for first-line therapy of patients with HER2-negative metastatic breast cancer (MBC)
Gluck, S.
Lobo, C.
Reis, I.
Lopes, G.
Carmody, C.
Tukia, K.
Hurley, J.
Seo, P.
Silva, O.
Slingerland, J.
Welsh, C.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[30] Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial
Lam, S. W.
de Groot, S. M.
Honkoop, A. H.
Jager, A.
ten Tije, A. J.
Bos, M. M. E. M.
Linn, S. C.
van den Bosch, J.
Kroep, J. R.
Braun, J. J.
van Tinteren, H.
Boven, E.
EUROPEAN JOURNAL OF CANCER, 2014, 50 (18) : 3077 - 3088

← 1 2 3 4 5 →